SCHEMBL3928684

SCHEMBL3928684

COc1cccc(OC)c1CNC(=N)c1cc2ccccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.52
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
KDM4E B2RXH2 3/20 0.44
RAB9A P51151 3/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NPC1 O15118 2/20 0.43
DRD2 P14416 2/20 0.42
DRD3 P35462 2/20 0.42
DRD4 P21917 1/20 0.42
PDGFRB P09619 2/20 0.42
PDGFRA P16234 2/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27683033 0.88 FLT3 (0.53) FLT3MTNR1AMTNR1BKDM4ERAB9A
SCHEMBL3923810 0.87 KDM4E (0.53) FLT3KDM4ERAB9AALDH1A1MEN1
SCHEMBL3924095 0.87 FLT3 (0.47) FLT3KDM4EALDH1A1HPGDDRD3
SCHEMBL3935357 0.86 MEN1 (0.47) FLT3RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL6661201 0.85 FLT3 (0.58) FLT3MTNR1AMTNR1BKDM4ERAB9A
SCHEMBL6657213 0.79 FLT3 (0.54) FLT3MTNR1AMTNR1BKDM4ERAB9A
SCHEMBL3924063 0.78 PDGFRB (0.46) MTNR1AMTNR1BKDM4EALDH1A1MEN1
SCHEMBL6664487 0.77 KDM4E (0.55) FLT3MTNR1AMTNR1BKDM4ERAB9A
Hydrochloric Acid SCHEMBL3926581 0.76 IDO1 (0.52) FLT3KDM4ERAB9AALDH1A1MEN1
SCHEMBL6657806 0.76 DRD2 (0.54) FLT3MTNR1AMTNR1BKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773770-B1 INDOLE-2-CARBOXAMIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT (HU) 2009-04-01 EP claimed
US-20090048303-A1 Indole-2-carboxamidine derivatives as nmda receptor antago RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2009-02-19 US claimed
EP-1773770-A1 INDOLE-2-CARBOXAMIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS Richter Gedeon Vegy Szeti Gy R Rt. (HU) 2007-04-18 EP claimed
WO-2006010965-A1 INDOLE-2 -CARBOXAMIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-02-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048303-A1 Indole-2-carboxamidine derivatives as nmda receptor antago GRIN3A, GRIN1, GRIN2C FLT3 483/4885MTNR1A 39/4885MTNR1B 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.